Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q2FY27 revenue INR7,404 Cr, +4% Q-o-Q; EBITDA margin 18.7%, +200 bps Q-o-Q - One India business grew 12% Y-o-Y with strong chronic portfolio growth; launches in respiratory, antidiabetes, cardiovascular - North America revenue $172M, targeting $1B exit run rate FY27 with 3 major launches pending - Biosimilars pipeline advancing; partnership with Qilu for Pembrolizumab in North America - FDA inspections: Invagen Long Island cleared with 0 observations; Pithampur facility has 7 observations, remediation ongoing - R&D spend at 5.7% of revenue this quarter; full year guidance 6-7% - Net cash position INR9,823 Cr; debt INR699 Cr including leases - Multiple analyst queries on US ramp-up; management confident on achieving $1B run rate via existing and new product launches - Domestic branded prescription business outperformed market with 15% growth; consumer health showing steady growth - EBITDA margin guidance maintained at 18.5-20% for FY27